XTENT
Founded Year
2002Stage
Unattributed VC - II | DeadTotal Raised
$55.39MLast Raised
$30MAbout XTENT
Based in Menlo Park, California, Xtent Inc. is a privately held developer of next generation drugeluting stent (DES) systems designed for the treatment of real-world patients, including those with complex, multi-lesion or multi-vessel coronary and peripheral vascular disease. Although the drugeluting stent (DES) market is today dominated by large companies, the interventional cardiology field has seen many technological breakthroughs that have changed market leadership.
Loading...
Loading...
XTENT Patents
XTENT has filed 18 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/21/2012 | 7/11/2017 | Implants (medicine), Vascular diseases, Prosthetics, Interventional radiology, Medical equipment | Grant |
Application Date | 11/21/2012 |
|---|---|
Grant Date | 7/11/2017 |
Title | |
Related Topics | Implants (medicine), Vascular diseases, Prosthetics, Interventional radiology, Medical equipment |
Status | Grant |
Latest XTENT News
Apr 6, 2022
In this review we look at the Crua XTENT Combo Maxx, now available and is priced at €900. See more on their website here. Crua XTENT Combo Maxx reviewed With the Easter break nearly upon us, thoughts turn to holidays later in the year. Ireland is actually a potentially promising place for camping too. Sure no […]
XTENT Frequently Asked Questions (FAQ)
When was XTENT founded?
XTENT was founded in 2002.
Where is XTENT's headquarters?
XTENT's headquarters is located at 125 Constitution Drive, Menlo Park.
What is XTENT's latest funding round?
XTENT's latest funding round is Unattributed VC - II.
How much did XTENT raise?
XTENT raised a total of $55.39M.
Who are the investors of XTENT?
Investors of XTENT include Morgenthaler Ventures, Advanced Technology Ventures, Split Rock Partners, St. Paul Venture Capital, Latterell Venture Partners and 4 more.
Who are XTENT's competitors?
Competitors of XTENT include Reva Medical, Benvenue Medical, Endologix, Neuro Kinetics, NeoGraft Technologies and 7 more.
Loading...
Compare XTENT to Competitors
Endologix is a company focused on the development and manufacturing of minimally invasive treatments for aortic disorders, operating within the medical devices industry. The company's main offerings include a variety of endovascular stent grafts, which are used for the treatment of abdominal aortic aneurysms (AAA), a condition characterized by a weakening of the wall of the aorta that can lead to a balloon-like enlargement. Endologix primarily serves the healthcare sector, particularly in areas related to vascular disease and aortic disorders. It was founded in 1992 and is based in Irvine, California.
Reva Medical is a company that focuses on bioresorbable polymer technologies within the vascular applications sector. The company's main offerings include the development and sale of implantable medical devices designed to treat vascular conditions such as coronary and peripheral artery disease. These devices, made from a proprietary polymer, are designed to support the artery during the healing process and then naturally dissolve in the body. It was founded in 1998 and is based in San Diego, California.
Veryan is developing innovative solutions to improve the performance of vascular stents using the principles of biomimicry. Veryan's BioMimics 3D stent technology involves adapting traditional straight stent designs to a patented three-dimensional helical shape, which more closely mimics the natural geometry of the human vascular system. BioMimics 3D technology has been proven to enhance clinical performance by improving flow conditions in, and the biomechanical performance of, stented vessels. The advanced, biomimetic design of the BioMimics 3D stent is intended to provide improved flow conditions and more flexibility, kink and fracture resistance than other nitinol stents. Veryan's Research & Development facility is located in Galway, Ireland.
PeriTec is a Cleveland, Ohio based company that aims to develop vascular and cardiovascular surgical products. The company's technology involves the incorporation of a biological tissue, peritoneum, into implantable peripheral vascular stents and vascular patches.
Devices for the prevention of embolic complications including stroke and heart attack during interventional vascular procedures. Acquired by Boston Scientific in 2001.
InfraReDx is a company that focuses on the development of high-resolution intravascular imaging technologies, operating within the healthcare and technology sectors. The company's main offerings include imaging systems and devices that provide detailed structural views and plaque compositional analysis, aiding in the treatment of vascular diseases. InfraReDx primarily serves the healthcare industry, particularly sectors dealing with heart and vascular diseases. It was founded in 1998 and is based in Burlington, Massachusetts.
Loading...